Developer docs
API playgroundTry for free, no card

Search company profiles

Arpeggio Bio

Full company profile

uuid0000d5o

Namestring
Arpeggio Bio
Legal namestring
Arpeggio Bioscience Inc.
Websiteurl
arpeggiobio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Arpeggio Bio (legal name: Arpeggio Bioscience Inc.) is a preclinical-stage pharmaceutical company founded in 2017 and headquartered at 4888 Pearl East Circle, Suite 110E in Boulder, Colorado. The company develops an AI-enabled drug discovery platform that combines functional genomics, biological assays, and machine learning to analyze how drugs affect cellular transcriptomes, with the explicit goal of targeting transcription factors that have historically been considered undruggable. Its core products are a proprietary transcription-monitoring technology platform and a preclinical drug pipeline focused initially on lung cancer and broader cancers driven by transcriptional dysregulation, including programs centered on NRF2 and transcriptional addiction mechanisms such as CDK7 inhibition.

The platform's technical architecture uses biological assays to perturb cells with drug candidates and then applies machine learning to RNA expression readouts, enabling systematic discovery of therapeutic targets and characterization of drug function at the transcriptome level. This capability is intended to overcome a long-standing limitation in oncology drug discovery: transcription factors regulate gene expression programs underlying many cancers but have resisted traditional small-molecule approaches. Arpeggio's founding team includes CEO Joey Azofeifa, PhD in Computer Science from the University of Colorado, whose graduate work at the AI-cancer genomics intersection produced the founding IP, and co-founder Tim Read, PhD in Molecular Biology, who leads discovery biology efforts.

The business model is preclinical-stage R&D with no commercialized products, no disclosed pricing, and no revenue-generating customers at present. The company has raised over $60 million cumulatively across multiple rounds (including a $17 million Series A led by Builders VC in September 2022 and a $20 million round in November 2025) from institutional life-sciences investors including Khosla Ventures, Tencent, Westlake BioPartners, venBio, and Y Combinator. Go-to-market will ultimately depend on internal clinical development, out-licensing of pipeline assets, or partnerships with larger pharmaceutical companies, none of which have been disclosed to date.

Short descriptiontext

Arpeggio Bio is a preclinical-stage biotech using an AI-enabled transcriptomic screening platform to discover small-molecule therapeutics targeting transcription factors, with an initial pipeline focus on lung cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, transcription factor therapeutics, functional genomics research, AI drug screening, cancer drug development
Industry3 codes
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Drug Discovery
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arpeggio Bio is a preclinical-stage pharmaceutical company developing an AI-enabled transcription-monitoring platform that combines functional genomics, biological assays, and machine learning to measure how drugs affect cellular transcriptomes. The company uses this platform to discover and advance drug candidates against historically 'undruggable' transcription factors that drive hard-to-treat diseases, with an initial focus on lung cancer.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Arpeggio Bio is a preclinical-stage pharmaceutical company developing a drug discovery platform that combines functional genomics with machine learning to analyze how drugs affect cellular transcriptomes. The company's core technology is its transcription-monitoring platform, which uses biological assays and AI to measure drug effects on RNA expression patterns, specifically targeting difficult-to-drug transcription factors. The company is applying this platform to discover and develop therapies for cancer and other diseases caused by transcriptional dysregulation, with a focus on lung cancer and undruggable transcription factor targets.

Product and service2 records
1Transcription-Monitoring Technology Platform
CategoryDrug discovery platform
Description

Proprietary AI-enabled platform that measures the effects of drugs on cellular transcriptomes by combining biological assays with machine learning. Used internally to discover and validate therapeutic targets, including historically difficult-to-drug transcription factors, in diseases such as cancer.

2Drug Pipeline for Transcription Factor Targets
CategoryPreclinical drug pipeline
Description

Preclinical-stage pipeline of therapeutic candidates targeting transcription factors and transcriptional addiction mechanisms in cancer, with programs including NRF2 and other lung cancer targets. Currently in preclinical development with no commercialized products.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage AI-driven drug discovery company combining high-throughput biology with machine learning. Like Arpeggio, Recursion uses functional/phenotypic screening at scale to identify novel therapeutic targets, including historically difficult ones.

TypeDirect peer
Description

Machine learning-driven drug discovery company that combines high-throughput biology with AI/ML to identify targets and develop therapeutics. Directly comparable to Arpeggio in applying AI/ML to functional genomics for novel target identification.

TypeDirect peer
Description

Computational chemistry and AI-driven drug discovery platform company serving both internal pipeline and external pharma collaborators. Comparable to Arpeggio in leveraging computational methods to address difficult-to-drug targets.

TypeDirect peer
Description

AI-driven precision medicine and drug discovery company with clinical-stage assets. Comparable to Arpeggio in using AI to design and prioritize drug candidates, including against challenging target classes.

TypeDirect peer
Description

AI-driven small molecule drug discovery company using structure-based deep learning models. Comparable to Arpeggio in pursuing AI-enabled approaches to drug historically difficult targets, with active pharma partnerships.

6Isomorphic Labs
TypeDirect peer
Description

Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction and computational biology to drug discovery. Comparable to Arpeggio in leveraging AI to tackle targets (including transcription factors and protein-protein interactions) historically resistant to small-molecule approaches.

TypeEmerging player
Description

Flagship Pioneering-founded AI/generative biology company designing novel protein therapeutics. Comparable to Arpeggio in applying ML to biology for novel therapeutic generation against difficult targets.

TypeEmerging player
Description

AI-driven drug discovery company combining physics-based modeling with ML for small molecule design. Comparable to Arpeggio in using AI/ML for computational drug design across difficult target classes.

9Syros Pharmaceuticals
TypeEmerging player
Description

Clinical-stage biopharma focused on gene regulation and transcriptional dysregulation, including CDK7 inhibitors. Highly relevant comparable given Arpeggio Senior Scientist Jenna Rimel's prior collaboration with Syros on CDK7 inhibitors and overlapping transcription factor targeting space.

10Forma Therapeutics
TypeEmerging player
Description

Biopharmaceutical company targeting rare hematologic diseases and cancers, including transcription factor and protein-protein interaction targets. Comparable given CEO Joey Azofeifa's prior role at Forma, and overlapping focus on difficult oncology targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arpeggio Bio

Drug Discoveryarpeggiobio.com

Arpeggio Bio is a preclinical-stage biotech using an AI-enabled transcriptomic screening platform to discover small-molecule therapeutics targeting transcription factors, with an initial pipeline focus on lung cancer.

What Arpeggio Bio does

Arpeggio Bio (legal name: Arpeggio Bioscience Inc.) is a preclinical-stage pharmaceutical company founded in 2017 and headquartered at 4888 Pearl East Circle, Suite 110E in Boulder, Colorado. The company develops an AI-enabled drug discovery platform that combines functional genomics, biological assays, and machine learning to analyze how drugs affect cellular transcriptomes, with the explicit goal of targeting transcription factors that have historically been considered undruggable. Its core products are a proprietary transcription-monitoring technology platform and a preclinical drug pipeline focused initially on lung cancer and broader cancers driven by transcriptional dysregulation, including programs centered on NRF2 and transcriptional addiction mechanisms such as CDK7 inhibition.

The platform's technical architecture uses biological assays to perturb cells with drug candidates and then applies machine learning to RNA expression readouts, enabling systematic discovery of therapeutic targets and characterization of drug function at the transcriptome level. This capability is intended to overcome a long-standing limitation in oncology drug discovery: transcription factors regulate gene expression programs underlying many cancers but have resisted traditional small-molecule approaches. Arpeggio's founding team includes CEO Joey Azofeifa, PhD in Computer Science from the University of Colorado, whose graduate work at the AI-cancer genomics intersection produced the founding IP, and co-founder Tim Read, PhD in Molecular Biology, who leads discovery biology efforts.

The business model is preclinical-stage R&D with no commercialized products, no disclosed pricing, and no revenue-generating customers at present. The company has raised over $60 million cumulatively across multiple rounds (including a $17 million Series A led by Builders VC in September 2022 and a $20 million round in November 2025) from institutional life-sciences investors including Khosla Ventures, Tencent, Westlake BioPartners, venBio, and Y Combinator. Go-to-market will ultimately depend on internal clinical development, out-licensing of pipeline assets, or partnerships with larger pharmaceutical companies, none of which have been disclosed to date.

Arpeggio Bio firmographics

Firmographics
Name
Arpeggio Bio
Legal name
Arpeggio Bioscience Inc.
Website
https://arpeggiobio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Arpeggio Bio is a preclinical-stage biotech using an AI-enabled transcriptomic screening platform to discover small-molecule therapeutics targeting transcription factors, with an initial pipeline focus on lung cancer.
Ownership category
akta.pro rank

Arpeggio Bio industry classification

Industry
Product category
Drug Discovery
NAICS
Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug discovery platform
  • Transcription factor therapeutics
  • Functional genomics research
  • AI drug screening
  • Cancer drug development

Where Arpeggio Bio is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Arpeggio Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Marketing channels1 record

Arpeggio Bio product offering

Product offering

Core offering

Arpeggio Bio is a preclinical-stage pharmaceutical company developing an AI-enabled transcription-monitoring platform that combines functional genomics, biological assays, and machine learning to measure how drugs affect cellular transcriptomes. The company uses this platform to discover and advance drug candidates against historically 'undruggable' transcription factors that drive hard-to-treat diseases, with an initial focus on lung cancer.

Product overview

Arpeggio Bio is a preclinical-stage pharmaceutical company developing a drug discovery platform that combines functional genomics with machine learning to analyze how drugs affect cellular transcriptomes. The company's core technology is its transcription-monitoring platform, which uses biological assays and AI to measure drug effects on RNA expression patterns, specifically targeting difficult-to-drug transcription factors. The company is applying this platform to discover and develop therapies for cancer and other diseases caused by transcriptional dysregulation, with a focus on lung cancer and undruggable transcription factor targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Transcription-Monitoring Technology Platform Proprietary AI-enabled platform that measures the effects of drugs on cellular transcriptomes by combining biological assays with machine learning. Used internally to discover and validate therapeutic targets, including historically difficult-to-drug transcription factors, in diseases such as cancer.
  • Drug Pipeline for Transcription Factor Targets Preclinical-stage pipeline of therapeutic candidates targeting transcription factors and transcriptional addiction mechanisms in cancer, with programs including NRF2 and other lung cancer targets. Currently in preclinical development with no commercialized products.

Companies that use Arpeggio Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Arpeggio Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Arpeggio Bio partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Arpeggio Bio competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining high-throughput biology with machine learning. Like Arpeggio, Recursion uses functional/phenotypic screening at scale to identify novel therapeutic targets, including historically difficult ones.
  • Insitro: Machine learning-driven drug discovery company that combines high-throughput biology with AI/ML to identify targets and develop therapeutics. Directly comparable to Arpeggio in applying AI/ML to functional genomics for novel target identification.
  • Schrödinger: Computational chemistry and AI-driven drug discovery platform company serving both internal pipeline and external pharma collaborators. Comparable to Arpeggio in leveraging computational methods to address difficult-to-drug targets.
  • Exscientia: AI-driven precision medicine and drug discovery company with clinical-stage assets. Comparable to Arpeggio in using AI to design and prioritize drug candidates, including against challenging target classes.
  • Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning models. Comparable to Arpeggio in pursuing AI-enabled approaches to drug historically difficult targets, with active pharma partnerships.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's protein structure prediction and computational biology to drug discovery. Comparable to Arpeggio in leveraging AI to tackle targets (including transcription factors and protein-protein interactions) historically resistant to small-molecule approaches.

Emerging players

  • Generate Biomedicines: Flagship Pioneering-founded AI/generative biology company designing novel protein therapeutics. Comparable to Arpeggio in applying ML to biology for novel therapeutic generation against difficult targets.
  • XtalPi: AI-driven drug discovery company combining physics-based modeling with ML for small molecule design. Comparable to Arpeggio in using AI/ML for computational drug design across difficult target classes.
  • Syros Pharmaceuticals: Clinical-stage biopharma focused on gene regulation and transcriptional dysregulation, including CDK7 inhibitors. Highly relevant comparable given Arpeggio Senior Scientist Jenna Rimel's prior collaboration with Syros on CDK7 inhibitors and overlapping transcription factor targeting space.
  • Forma Therapeutics: Biopharmaceutical company targeting rare hematologic diseases and cancers, including transcription factor and protein-protein interaction targets. Comparable given CEO Joey Azofeifa's prior role at Forma, and overlapping focus on difficult oncology targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Arpeggio Bio social profiles

Digital presence

Arpeggio Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arpeggio Bio leadership team

Management profile

Number of profiles

Profiles14 records

Arpeggio Bio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arpeggio Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arpeggio Bio

What does Arpeggio Bio do?

Arpeggio Bio is a preclinical-stage pharmaceutical company developing an AI-enabled transcription-monitoring platform that combines functional genomics, biological assays, and machine learning to measure how drugs affect cellular transcriptomes. The company uses this platform to discover and advance drug candidates against historically 'undruggable' transcription factors that drive hard-to-treat diseases, with an initial focus on lung cancer.

Is Arpeggio Bio a public or private company?

Arpeggio Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Arpeggio Bio founded?

Arpeggio Bio was founded in 2017. It employs 1 to 10 people.

Where is Arpeggio Bio based?

Arpeggio Bio is headquartered in Boulder, United States, in the North America region.

Who are Arpeggio Bio's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Schrödinger, Exscientia, Atomwise and Isomorphic Labs. Emerging players are Generate Biomedicines, XtalPi, Syros Pharmaceuticals and Forma Therapeutics.

Does Arpeggio Bio have an API?

No public API is recorded for Arpeggio Bio.

What industry is Arpeggio Bio in?

Arpeggio Bio's product category is Drug Discovery. Its primary akta.pro industry code is HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechArpeggio plays final chord as biotech disbands on poor prospects for Nrf2 programArpeggio Biosciences, an eight-year-old Boulder, Colorado-based biotech company, has shut down after its Nrf2 small molecule program for non-small cell lung cancer failed due to an inability to separate drug efficacy from an off-target liability. The company had raised a $17 million Series A in 2022 from Builders VC, Khosla Ventures and TechU Ventures, and conducted over 300,000 transcriptome sequences and created more than 2,000 proprietary small molecules across four drug programs before the program unraveled. The company's website is no longer accessible and the number of affected employees remains unclear.SecSEC FORM DArpeggio Biosciences, Inc., a Colorado-based biotechnology company, filed a Form D notice with the SEC on November 19, 2025, for an exempt offering of equity securities under Rule 506(b) and 506(c). The filing indicates a total offering amount of $35,318,765, with $20,037,075 already sold to 12 investors as of the first sale on November 12, 2025, leaving $15,281,690 remaining. The company, incorporated in Delaware over five years ago, disclosed revenue as undisclosed and reported zero sales commissions or finder fees.SecSEC FORM DArpeggio Biosciences, Inc. filed a Form D with the SEC reporting an exempt offering of securities under Rule 506(b). The company raised approximately $20.25 million from 28 investors, leaving a negligible remaining amount to be sold. This filing discloses the details of the private equity transaction conducted in August 2022.FinSMEsArpeggio Biosciences Raises $17M in Series A FundingArpeggio Biosciences raised $17M in Series A funding led by Builders VC, following a $3.2M seed round. The company will use the funds to advance its drug pipeline and transcription-monitoring technologies. The Boulder-based firm's platform reads out on transcription and can monitor over 100,000 transcripts.trib.alArpeggio Biosciences rakes in $17M to measure the transcriptomeArpeggio Biosciences closed a $17 million Series A round, bringing total funding to over $20 million. The Boulder-based startup's platform measures transcriptome activity from over 100,000 mRNA transcripts, and it will use half the funds to mature its drug pipeline and half to scale pharma partnerships.PharmiWeb.comArpeggio Biosciences Raises $17 Million in Series A Funding Led by Builders VCArpeggio Biosciences announced a $17 million Series A funding round led by Builders VC to support the development of its drug pipeline and transcription-monitoring technologies. The company utilizes a proprietary platform combining biological assays and machine learning to screen for modulators of 'undruggable' proteins like transcription factors. Additional investors in the round included Khosla Ventures, Tencent, and several other venture capital firms.Business Wire BlogArpeggio Biosciences Raises $17 Million in Series A Funding Led by Builders VCArpeggio Biosciences announced a $17 million Series A funding round led by Builders VC to support the development of its drug pipeline and transcription-monitoring technologies. The company's platform utilizes machine learning to screen drug libraries against entire transcriptomes, aiming to discover modulators for hard-to-drug proteins like transcription factors. Previous investors including Khosla Ventures also participated in the round alongside new backers such as Tencent.Financial PostArpeggio Biosciences Raises $17 Million in Series A Funding Led by Builders VCArpeggio Biosciences has raised $17 million in a Series A funding round led by Builders VC to support the development of its drug pipeline targeting transcriptional mechanisms. The company's proprietary technology isolates a drug’s effect on entire transcriptomes and has already contracted with over 40 pharmaceutical companies to assess molecular impacts.VC News DailyArpeggio Biosciences Raises $17M in Series AArpeggio Biosciences announced the closing of a $17 million Series A funding round led by Builders VC. The investment was supported by existing seed investors including Khosla Ventures and Tencent, as well as new participants such as ATEM Capital and Formic Ventures. This capital will support the preclinical therapeutics company's development of technologies targeting transcriptional dysregulation in disease.